This could be explained by a finding that obese patients with MASLD have increased IFNα and decreased IFNγ levels, and IFNα but not IFNγ levels are associated with the accumulation of intramuscular fat, an important contributor to insulin resistance [59]. The gene discussed is IFNA1; the disease is metabolic dysfunction-associated steatotic liver disease.